ASX 200 drops 2.5%, ASX travel shares dumped

The S&P/ASX 200 Index (ASX:XJO) fell by around 2.5%. COVID-19 worries are intensifying again as case numbers keep rising.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) dropped 2.5% today to 5,818 points.

Investors are becoming more fearful about the spread of COVID-19 again. The S&P 500 (INX) fell by 2.6% overnight and the ASX generally follows what international share markets do in the short-term.

a woman

ASX travel shares and banks sell off

Some of the ASX 200 shares that are most at risk of another COVID-19 uncontrolled outbreak were the ones that fell the most today.

The share price of Flight Centre Travel Group Ltd (ASX: FLT) fell by 11%.

Webjet Limited (ASX: WEB) suffered a share price decline of 8.6%.

The Corporate Travel Management Ltd (ASX: CTD) share price dropped 8%.

It wasn't just ASX 200 travel shares that declined today.

The Commonwealth Bank of Australia (ASX: CBA) share price fell 2.3%, the Westpac Banking Corp (ASX: WBC) share price dropped 3.5%, the Australia and New Zealand Banking Group (ASX: ANZ) share price declined 3.1% and the National Australia Bank Ltd (ASX: NAB) share price dropped 3.5%.

CSL Limited's (ASX: CSL) deal

Healthcare leader CSL announced it is going to acquire the exclusive global license rights to commercialise an adeno-associated virus (AAV) gene therapy program called AMT-061 for the treatment of haemophilia B. The AMT-061 program, currently in phase 3 clinical trials, could be one of the first gene therapies to provide potential long-term benefits to patients with haemophilia B.

If AMT-061 is successful, appropriate candidate haemophilia B patients would be able to have a one-time treatment to restore factor IX plasma level activity to functional levels capable of eliminating the need for frequent and ongoing replacement therapies.

The ASX 200 business will start with an upfront US$450 million payment to uniQure followed by regulatory and commercial sales milestone payments and royalties.

Qantas Airways Limited (ASX: QAN) turnaround plan

Qantas has announced a $1.9 billion capital raising to help the business remain financially strong during the next three years.

It is looking to raise approximately $1.4 billion in a fully underwritten institutional placement and up to $500 million in a non-underwritten share purchase plan. The placement price is $3.65 per share, which is a 12.9% discount to the last traded price. The new shares represent a 25% increase to the total shares on issue.

Qantas unveiled a plan that is targeting $15 billion of lower costs over three years in line with reduced flying activity including fuel consumption savings. It hopes to achieve $1 billion per annum of ongoing cost savings from FY23 with productivity improvements.

The ASX 200 airline is going to cut 6,000 jobs across all parts of the business. It will continue to stand down 15,000 employees, particularly those associated with international operations. It will also ground up to 100 of its aircraft for up to 12 months (or more). Some leased aircraft may be returned as they fall due.

The cost of implementing this plan is expected to cost $1 billion with most of it realised during FY21.

Bapcor Ltd (ASX: BAP) reports large growth

Bapcor announced it has seen a large amount of sales growth for two of its main divisions.

The ASX 200 auto parts business said its retail segment experienced strong demand in May and June with Autobarn same store sales increasing over 45% from the prior year. On a full year basis to the end of June 2020, it is estimated that Autobarn same store sales will increase by approximately 8%.

Burson Trade has also experienced strong demand in May and June with same store sales growth to be up approximately 10%. On a full year basis, Burson same store sales growth is expected to be around 5%.

Bapcor's segments that suffered most heavily due to COVID-19 were New Zealand, specialist wholesale and Thailand. These segments are also recovering.

Management is now experiencing net profit after tax (before significant items) for FY20 to be in the range of $84 million to $88 million.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Bapcor, Corporate Travel Management Limited, and Webjet Ltd. The Motley Fool Australia has recommended Flight Centre Travel Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »